Objectives To report the first and largest systematic review and meta-analysis of randomized
controlled trials (RCT) to evaluate the efficacy and safety of aripiprazole or bupropion …

Background Treatment-resistant depression (TRD) is common and potentially life-
threatening in adults, and the benefits and risks of adjunctive aripiprazole in these patients …

No study has directly compared the efficacy and tolerability of aripiprazole augmentation
(AA) and antidepressant switching (SW) in patients with major depressive disorder (MDD) …

Importance Less than one-third of patients with major depressive disorder (MDD) achieve
remission with their first antidepressant. Objective To determine the relative effectiveness …

There has been no studies comparing the clinical benefits of aripiprazole augmentation
(AT), antidepressant combination (AC), and switching to a different antidepressant (SW) in …

Aims: Augmentation therapy is an option for patients with major depressive disorder who do
respond sufficiently to adequate dosages of selective serotonin reuptake inhibitors or …

Objective: To determine whether switching within or between antidepressant therapy (ADT)
classes prior to the use of adjunctive antipsychotic treatment is associated with different …

Background Several studies have evaluated the efficacy and tolerability of aripiprazole for
augmentation of antidepressant therapy for treatment-resistant depression (TRD). Here, we …

Objective The present study is to provide whether open-label studies (OLS) may properly
foresee the efficacy of randomized, placebo-controlled trials (RCTs) using OLSs and RCTs …

Methods: The cost-effectiveness analysis was conducted as part of a randomized clinical
trial, the Veterans Affairs Augmentation and Switching Treatments for Improving Depression …